Aspira women's health provides commercial, reimbursement and cash guidance updates

Monthly ovasuitesm  product volume grew by more than 26% in may compared to january reimbursement momentum continued with expanded anthem and medicaid coverage for ovasuite cash used in operations guidance for 2024 expected to be lowered austin, texas, june 13, 2024 (globe newswire) -- aspira women's health inc. (“aspira” or the “company”) (nasdaq: awh), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today provided interim commercial and operational updates for the second quarter of 2024. product volume continued its sustained monthly gains, growing by more than 26% in may 2024 compared to january 2024.
AWH Ratings Summary
AWH Quant Ranking